{"disease":{"id":"relapsed-ovarian-cancer-brca-mutation-platinum-sensitivity","name":"relapsed ovarian cancer brca mutation platinum sensitivity"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02983799","title":"Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02282020","title":"Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":266,"lead_sponsor_name":"AstraZeneca","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}